【摘要】 国家药品监督管理局要求自2023年7月31日起，启动的药物临床研究的相关要求适用《E14:非抗心律失常药物致QT/QTc间期延长及潜在致心律失常作用的临床评价》。本文就QT间期和QTc、可能引发QT间期延长甚至尖端扭转型室性心动过速的非抗心律失常药物、QT间期延长的影响机制以及易患因素等有关问题进行介绍，旨在提醒临床密切关注非抗心律失常新药对QT/QTc间期的影响，以提高药物使用的安全性。更多还原

【Abstract】 The National Medical Products Administration demands that the relevant requirements for drug clinical studies initiated since July 31, 2023 follow the “E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs”. This paper introduces QT interval and QTc, non-antiarrhythmic drugs potentially leading to QT interval prolongation and even torsade de pointes, the mechanism of QT interval prolongation, predisposing factors, and other related issues. It is aimed to arouse more attention to the effects of new non-antiarrhythmic drugs on QT/QTc interval among clinicians, and to improve the safety of drug use.更多还原